Use of aminosalicylates in diarrhoea-predominent irritable bowel syndrome

Abstract

A method for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhoea-predominant irritable bowel syndrome or other non-specific bowel disorder is disclosed comprising administering to a patient in need of such treatment or prophylaxis an effective amount of balsalazide, or a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or a derivative thereof, or a composition comprising balsalazide the modified compound, or a salt or a derivative thereof together with a suitable carrier. Use of balsalazide, a 4-ASA or 5-ASA compound modified to include a 4-ABA side chain, or a salt or derivative thereof, for the manufacture of a medicament for the treatment or prophylaxis of non-inflammatory bowel diseases, diarrhoea-predominant Irritable Bowel Syndrome or other non-specific bowel disorder is also disclosed.

1 - 13 . (canceled) 
     
     
         14 . A method for the treatment or prophylaxis of diarrhoea-predominant irritable bowel syndrome comprising administering to a human patient in need of such treatment or prophylaxis from about 500 mg to about 6 grams of balsalazide or a salt thereof and rifaximin. 
     
     
         15 . A method for the treatment or prophylaxis of alternating diarrhoea and constipation type irritable bowel syndrome comprising administering to human a patient in need of such treatment or prophylaxis from about 500 mg to about 6 grams of balsalazide or a salt thereof and rifaximin. 
     
     
         16 . A method for the treatment or prophylaxis of constipation-predominant type irritable bowel syndrome comprising administering to a human patient in need of such treatment or prophylaxis from about 500 mg to about 6 grams of balsalazide or a salt thereof and rifaximin. 
     
     
         17 . The method of  claim 14 , wherein the disodium salt of balsalazide is administered. 
     
     
         18 . The method of  claim 15 , wherein the disodium salt of balsalazide is administered. 
     
     
         19 . The method of  claim 16 , wherein the disodium salt of balsalazide is administered. 
     
     
         20 . The method of  claim 14 , wherein the balsalazide is administered orally. 
     
     
         21 . The method of  claim 15 , wherein the balsalazide is administered orally. 
     
     
         22 . The method of  claim 16 , wherein the balsalazide is administered orally. 
     
     
         23 . The method of  claim 17 , wherein the balsalazide is administered orally. 
     
     
         24 . The method of  claim 18 , wherein the balsalazide is administered orally. 
     
     
         25 . The method of  claim 19 , wherein the balsalazide is administered orally. 
     
     
         26 . The method of  claim 23 , wherein from about 1 gram to about 4 grams of balsalazide is administered. 
     
     
         27 . The method of  claim 24 , wherein from about 1 gram to about 4 grams of balsalazide is administered. 
     
     
         28 . The method of  claim 25 , wherein from about 1 gram to about 4 grams of balsalazide is administered. 
     
     
         29 . The method of  claim 26 , wherein from about 3 grams of balsalazide is administered. 
     
     
         30 . The method of  claim 27 , wherein from about 3 grams of balsalazide is administered. 
     
     
         31 . The method of  claim 28 , wherein from about 3 grams of balsalazide is administered. 
     
     
         32 . The method of  claim 14 , wherein the balsalazide is administered twice or three times daily. 
     
     
         33 . The method of  claim 15 , wherein the balsalazide is administered twice or three times daily. 
     
     
         34 . The method of  claim 16 , wherein the balsalazide is administered twice or three times daily. 
     
     
         35 . The method of  claim 26 , wherein the balsalazide is administered twice or three times daily. 
     
     
         36 . The method of  claim 27 , wherein the balsalazide is administered twice or three times daily. 
     
     
         37 . The method of  claim 28 , wherein the balsalazide is administered twice or three times daily. 
     
     
         38 . The method of  claim 29 , wherein the balsalazide is administered twice or three times daily. 
     
     
         39 . The method of  claim 30 , wherein the balsalazide is administered twice or three times daily. 
     
     
         40 . The method of  claim 31 , wherein the balsalazide is administered twice or three times daily.